Syndax Pharmaceuticals Inc
No SEC Form 4 filings for $SNDX in the last 30 days.
See all $SNDX insider activity →Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase – • Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% ye
Syndax Pharmaceuticals (SNDX) outlined plans to expand Revuforj (menin inhibition) into myelofibrosis, including a Q4 proof-of-principle phase 1/2 trial in about 30 patients. It also expects to file an IND for SNDX-62122 in 2027. Syndax and Incyte are advancing axatilimab (Niktimvo) in chronic GVHD and IPF, and introduced SNDX-4321 for EGFR-mutant NSCLC with an IND expected by year-end.
Metzger Michael A (Chief Executive Officer) sold 32,375 shares of Syndax Pharmaceuticals Inc (SNDX) at $24.24 ($0.78M total) on 2026-07-08 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning SNDX (Syndax Pharmaceuticals Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SNDX coverage spans insider activity, technology and corporate actions.
Commercial momentum is strengthening (large YoY revenue growth and prescription growth), while near-term catalysts are tied to 4Q26 Phase 2 topline data for axatilimab.
The article expands Syndax’s clinical roadmap across myelofibrosis, IPF, and EGFR-mutant lung cancer, creating multiple upcoming decision points (trial starts and IND timing).
This is a routine insider sale disclosure, not a new operating or regulatory catalyst.
Routine 10b5-1 insider selling provides limited fundamental signal, but can slightly affect near-term sentiment for a small/mid-cap biotech.
Conference-stage clinical updates strengthen the revumenib efficacy narrative across multiple AML genetic subtypes and settings (real-world, post-HSCT, and combinations).
alphai scores every news story that mentions SNDX with an AI model for sentiment and relevance, and aggregates insider trades from Syndax Pharmaceuticals Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Syndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sndx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update • Total revenue of $73 million in 2Q26, a 92% year-over-year increase – • Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% ye
6 min readSyndax Pharmaceuticals (SNDX) outlined plans to expand Revuforj (menin inhibition) into myelofibrosis, including a Q4 proof-of-principle phase 1/2 trial in about 30 patients. It also expects to file an IND for SNDX-62122 in 2027. Syndax and Incyte are advancing axatilimab (Niktimvo) in chronic GVHD and IPF, and introduced SNDX-4321 for EGFR-mutant NSCLC with an IND expected by year-end.
7 min readMetzger Michael A (Chief Executive Officer) sold 32,375 shares of Syndax Pharmaceuticals Inc (SNDX) at $24.24 ($0.78M total) on 2026-07-08 under a Rule 10b5-1 trading plan.
1 min readBotwood Nicholas A.J. (Head of R&D, CMO) sold 65,515 shares of Syndax Pharmaceuticals Inc (SNDX) at an average of $18.07 ($18.00–$18.14, $1.18M total) across 2 trades over 2026-06-11 to 2026-06-12 under a Rule 10b5-1 trading plan.
2 min readSyndax Pharmaceuticals reported multiple Revuforj (revumenib) abstracts at EHA 2026. In ROAR (R/R NPM1m/KMT2Ar), interim ORR was 82% (9/11) with 64% (7/11) CR/CRh. In SNDX-5613-0708 (newly diagnosed NPM1m/KMT2Ar), CRc was 97% (34/35) and MRD negativity 86% (25/29). Post-HSCT AUGMENT-101 analysis showed 12-month OS 95%. In SAVE (R/R AML), ORR was 88% (37/42) and MRD negativity 68% (25/37).
6 min readSyndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 d105044dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version SYNDAX PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 10, 2026 2.25% Convertible Senior Notes due 2031 TABLE OF CONTENTS P AGE ARTICLE 1 DEFINITIO
6 min readSyndax Pharmaceuticals Inc (SNDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 sndx-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SYNDAX PHARMACEUTICALS, Inc. 2026 Equity Incentive Plan Adopted by the Board of Directors: April 30 , 2026 Approved by the Stockholders: June 10 , 2026 1. General. (a) Successor to and Continuation of Prior Plan . The Plan is
4 min readSyndax Pharmaceuticals (NASDAQ: SNDX) said it entered private subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031, with an expected June 10, 2026 closing. Net proceeds are estimated at about $243 million for general corporate purposes. Notes pay semiannual interest, mature June 15, 2031, and have an initial conversion price of ~$24.76/share.
4 min readMetzger Michael A (Chief Executive Officer) sold 6,847 shares of Syndax Pharmaceuticals Inc (SNDX) at $18.99 ($0.13M total) on 2026-06-01.
1 min readSyndax Pharmaceuticals (SNDX) reported a narrowed Q1 2026 net loss of US$42.7 million on revenues of US$64.9 million, showing progress towards profitability. The company aims to shift from a 165.6% loss to a 14.7% profit margin in three years, despite a current trailing twelve-month loss of US$243.2 million. While bullish investors highlight strong forecast growth and a P/S discount compared to peers, bearish arguments focus on high R&D costs and dependence on a few lead drugs.
2 min read
